

9 May 2022

Melissa Kostopoulos
Compliance Adviser, Listings Compliance (Melbourne)
Australian Securities Exchange – ASX Limited
525 Collins Street, Rialto,
North Tower Level 4
Melbourne VIC 3000

Email: Melissa.Kostopoulos@asx.com.au

Dear Melissa

Respiri Limited – Notification under s 708A(5)(e) of the Corporations Act

Respiri Limited (ASX:RSH) (Company) advises that it has issued 37,155,556 fully paid ordinary shares (New Shares) in accordance with the Company's ASX announcements of 2 May 2022, and 6 May 2022, regarding the Company successfully raising a total of \$1,672,000 (before costs) in a placement to institutional, sophisticated and professional investors (**Placement**) by the issue of New Shares at \$0.045 per New Share.

This notice is given by the Company under Section 708A(5)(e) of the Corporations Act 2001 (Cth) (Corporations Act).

The Company hereby confirms that:

1. The Company has issued 37,155,556 fully paid ordinary shares in the Company in relation to the Placement with an issue price of \$0.045 per share, without disclosure to investors under Part 6D.2 of the Corporations Act.
2. The Company is providing this notice under section 708A(5)(e) of the Corporations Act.
3. As at the date of this notice, the Company, as a disclosing entity under the Corporations Act, has complied with:
 - (a) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
 - (b) section 674 of the Corporations Act as it applies to the Company.
4. As at the date of this notice, there is no excluded information of the type referred to in sections 708A(7) or 708A(8) of the Corporations Act, which is required to be disclosed by the Company.

This ASX announcement dated 9 May 2022 has been authorised for release by the Board of Directors of Respiri Limited.

Yours sincerely,



Alastair Beard
Company Secretary
Respiri Limited

About Respi Limited

Respi is an e-Health SaaS company supporting respiratory health management. Its world-first technology detects wheeze, a typical symptom of asthma, COPD and respiratory disease to provide an objective measure of airway limitation. wheezo®, Respi's innovative technology, comprises an eHealth app combined with a simple, easy to use, handheld device. wheezo® is the first smart device to help improve asthma management by monitoring wheeze and documenting symptoms, signs, triggers, weather conditions and medication use. The asthma management platform also facilitates the sharing of data with caregivers, physicians and other health care professionals.

Respi's mission is to help improve quality of life for hundreds of millions of children and adults around the world and dramatically reduce hospital admissions and the economic burden of asthma. Respi Limited's operations are based in Melbourne, Australia.

For additional information about Respi and its products, please visit www.respi.co

About wheezo®

Developed in Australia, with the support of respiratory specialists and other healthcare professionals, the innovative wheezo® device analyses breath sounds for wheeze, and the eHealth App assists patients with managing their asthma by tracking symptoms, triggers, medication use and geo-specific weather conditions. The platform has been designed to extend asthma management beyond the clinic and make it easy to share information with doctors and make appropriate adjustments to asthma action plans. Better active management may lead to better outcomes and improved quality of life for the asthma patient.

For further information about wheezo®, follow the online link <https://wheezo.com>

wheezo® is a registered trademark of Respi Limited.